IMCR Relative Valuation
IMCR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, IMCR is overvalued; if below, it's undervalued.
Historical Valuation
Immunocore Holdings PLC (IMCR) is now in the Undervalued zone, suggesting that its current forward PS ratio of 4.31 is considered Undervalued compared with the five-year average of -44.82. The fair price of Immunocore Holdings PLC (IMCR) is between 113.24 to 305.25 according to relative valuation methord. Compared to the current price of 32.41 USD , Immunocore Holdings PLC is Undervalued By 71.38%.
Relative Value
Fair Zone
113.24-305.25
Current Price：32.41
71.38%
Undervalued
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
4.38
P/B
Median3y
7.01
Median5y
6.36
1.57
FCF Yield
Median3y
-0.32
Median5y
-2.90
Competitors Valuation Multiple
The average P/S ratio for IMCR's competitors is 63.14, providing a benchmark for relative valuation. Immunocore Holdings PLC Corp (IMCR) exhibits a P/S ratio of 4.31, which is -93.17% above the industry average. Given its robust revenue growth of 33.16%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Immunocore Holdings PLC (IMCR) currently overvalued or undervalued?
What is Immunocore Holdings PLC (IMCR) fair value?
How does IMCR's valuation metrics compare to the industry average?
What is the current P/B ratio for Immunocore Holdings PLC (IMCR) as of Jul 08 2025?
What is the current FCF Yield for Immunocore Holdings PLC (IMCR) as of Jul 08 2025?
What is the current Forward P/E ratio for Immunocore Holdings PLC (IMCR) as of Jul 08 2025?